Cargando…

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE

BACKGROUND: Demonstration of clinical benefits on disability progression measures is an important attribute of effective multiple sclerosis (MS) treatments. OBJECTIVE: Examine efficacy of daclizumab beta versus intramuscular (IM) interferon beta-1a on measures of disability progression in patient su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohan, Stanley, Kappos, Ludwig, Giovannoni, Gavin, Wiendl, Heinz, Selmaj, Krzysztof, Havrdová, Eva Kubala, Rose, John, Greenberg, Steven, Phillips, Glenn, Ma, Wei, Wang, Ping, Lima, Gabriel, Sabatella, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282160/ https://www.ncbi.nlm.nih.gov/pubmed/28984179 http://dx.doi.org/10.1177/1352458517735190

Ejemplares similares

Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
por: Benedict, Ralph HB, et al.
Publicado: (2017)

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2020)

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
por: Krueger, James G., et al.
Publicado: (2016)

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2016)

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
por: Kappos, Ludwig, et al.
Publicado: (2021)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program
por: Gold, Ralf, et al.
Publicado: (2016)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry
por: Ranganath, Thanmayi, et al.
Publicado: (2020)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)
por: Cohan, Stanley L., et al.
Publicado: (2021)

The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil
por: Lemos, Livia Lovato Pires de, et al.
Publicado: (2017)

Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study
por: Cohan, Stanley, et al.
Publicado: (2018)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Pharmacodynamic effects of daclizumab in the intrathecal compartment
por: Komori, Mika, et al.
Publicado: (2017)

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis
por: Foley, John F., et al.
Publicado: (2013)

Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care
por: Barnes, Christopher J., et al.
Publicado: (2013)

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Immunomodulatory activity of interferon-beta
por: Kasper, Lloyd H, et al.
Publicado: (2014)

Interferons Alpha, Beta, and Omega
por: Meager, Anthony
Publicado: (1998)

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis
por: Newsome, Scott D., et al.
Publicado: (2016)

Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial
por: Kamm, Christian Philipp, et al.
Publicado: (2012)

Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice
por: van Beers, Miranda M. C., et al.
Publicado: (2011)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells
por: Trinschek, Bettina, et al.
Publicado: (2015)

Multiple human beta interferon genes
Publicado: (1982)

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
por: Lin, Yen Chih, et al.
Publicado: (2015)

Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial
por: Kamm, Christian P., et al.
Publicado: (2014)

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis
por: Penner, Iris-Katharina, et al.
Publicado: (2012)

Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2019)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
por: Hellwig, Kerstin, et al.
Publicado: (2020)

Evidence for Long-Term Use of Intramuscular Interferon Beta-1a: An Overview of Relapse, Disability, and MRI Data from Selected Clinical Trials
por: Foley, John F., et al.
Publicado: (2013)

Results of sustained long-term use of interferon beta-1a in a community-based cohort of patients with relapsing multiple sclerosis
por: Cohan, Stanley, et al.
Publicado: (2015)

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
por: Scheibe, Franziska, et al.
Publicado: (2018)

Inhibition of suppressor T lymphocytes by murine interferon beta
Publicado: (1987)

Thrombotic microangiopathy associated with use of interferon-beta
por: Olea, Teresa, et al.
Publicado: (2012)

Interferon beta-1a–induced morphea
por: Bezalel, Spencer A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_08ue4t67cmfb00i52icv21t9kp